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Neurotrophins are key regulators of neuronal survival and differentiation during development. Activation of their
cognate receptors, Trk receptors, a family of receptor tyrosine kinases (RTKs), is pivotal for mediating the downstream
functions of neurotrophins. Recent studies reveal that cyclin-dependent kinase 5 (Cdk5), a serine/threonine kinase,
may modulate RTK signaling through phosphorylation of the receptor. Given the abundant expression of both Cdk5
and Trk receptors in the nervous system, and their mutual involvement in the regulation of neuronal architecture and
synaptic functions, it is of interest to investigate if Cdk5 may also modulate Trk signaling. In the current study, we
report the identification of TrkB as a Cdk5 substrate. Cdk5 phosphorylates TrkB at Ser478 at the intracellular
juxtamembrane region of TrkB. Interestingly, attenuation of Cdk5 activity or overexpression of a TrkB mutant lacking
the Cdk5 phosphorylation site essentially abolishes brain-derived neurotrophic factor (BDNF)–triggered dendritic
growth in primary hippocampal neurons. In addition, we found that Cdk5 is involved in BDNF-induced activation of
Rho GTPase Cdc42, which is essential for BDNF-triggered dendritic growth. Our observations therefore reveal an
unanticipated role of Cdk5 in TrkB-mediated regulation of dendritic growth through modulation of BDNF-induced
Cdc42 activation.
Citation: Cheung ZH, Chin WH, Chen Y, Ng YP, Ip NY (2007) Cdk5 is involved in BDNF-stimulated dendritic growth in hippocampal neurons. PLoS Biol 5(4): e63. doi:10.1371/
journal.pbio.0050063
Introduction
Neurotrophins are indispensable for multiple aspects of
neuronal development, such as the maintenance of neuronal
survival, regulation of neuronal architecture, and synaptic
plasticity. Members of the neurotrophins include the proto-
typic member nerve growth factor (NGF), brain-derived
neurotrophic factor (BDNF), neurotrophin (NT)–3, and NT-
4/5. Downstream responses of neurotrophins are transduced
by a family of receptor tyrosine kinases (RTKs) known as Trks,
and also the low-affinity neurotrophin receptor p75.
Although all neurotrophins bind p75, they associate with
different Trk receptors with rather remarkable selectivity.
NGF interacts selectively with TrkA, while BDNF and NT-4/5
bind preferentially to TrkB. NT-3, on the other hand,
associates with TrkC with high affinity, although it also binds
TrkA and TrkB with low affinity. Similar to other RTKs,
activation of Trks leads to dimerization and autophosphor-
ylation of the receptors, followed by the recruitment and
initiation of a myriad of signaling pathways including the Ras/
MAPK, PI3K, and PLCc pathways [1,2].
Interestingly, recent studies have demonstrated that
activity of cyclin-dependent kinase 5 (Cdk5), a serine/
threonine kinase, is required for the downstream actions of
a RTK, ErbB. Cdk5 was found to phosphorylate ErbB2/3, a
phosphorylation that is essential for the activation of the
receptors [3,4]. Cdk5 is a member of the cyclin-dependent
kinase family, but it is unique in several aspects. First of all, it
is activated by the neural-specific non-cyclin activators p35
and p39. Secondly, Cdk5 is not involved in the regulation of
cell cycle control, but is implicated in neuronal migration,
synapse functions/maintenance, and neuronal survival [5,6].
The importance of Cdk5 in neuronal development and
migration is underscored by the aberrant phenotypes
exhibited by mice lacking Cdk5 and its activators. Cdk5
knockout mice and p35/p39 double knockout mice both
exhibit perinatal death with severe cortical lamination
defects [7,8]. Furthermore, swollen soma and nuclear margin-
ation is evident in Cdk5-deficient neurons, implicating Cdk5
as an essential regulator of neuronal survival [7]. Interest-
ingly, truncation of the Cdk5 activator p35 into p25 has also
been associated with prolonged Cdk5 activation in a number
of neurodegenerative diseases [9], thus revealing that precise
regulation of Cdk5 activity is essential for maintenance of
neuronal survival [10]. Furthermore, an increasing number of
studies are pointing to an essential role of Cdk5 at the
synapse, where it is not only involved in the formation and
maintenance of synapses, but is also indispensable for the
regulation of synaptic transmission and synaptic plasticity [5].
While the mechanisms by which Cdk5 regulates such diverse
functions remain to be unraveled, the identification of ErbB
receptors as Cdk5 substrates suggests that Cdk5 may exert its
biological effects by modulating signaling pathways down-
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stream of RTK activation. This piece of evidence, together
with the abundant expression of Cdk5 and Trk receptors in
the nervous system and their shared implication in a number
of biological functions, prompted us to further examine if
Cdk5 also regulates the signaling of Trk receptors.
In the current study, we report the identification of TrkB as
a substrate of Cdk5. More importantly, we found that Cdk5-
mediated phosphorylation of TrkB is essential for BDNF-
induced dendritic growth through the modulation of Cdc42
activity. Our findings provide evidence for a crosstalk
between the Cdk5 and neurotrophin signaling pathways,
and lend further support to the idea that Cdk5 is a modulator
of RTK signaling.
Results
TrkB Interacted with p35 and Cdk5
Given the increasing evidence implicating Cdk5 in the
modulation of RTK signaling, we sought to examine if Cdk5
may also play a role in Trk signaling. Literature search
revealed that TrkA, TrkB, and TrkC all contain serine- or
threonine-directed proline residues at the intracellular
juxtamembrane region of the receptors, but only TrkB and
TrkC contain Cdk5 consensus sites S/TPXK/H/R (Figure 1A).
To explore the potential interplay between Trk receptors and
Cdk5, we first examined if Trk receptors associated with Cdk5
or p35. TrkA, TrkB, or TrkC was overexpressed together with
Cdk5 or p35 in COS7 cells, and immunoprecipitation was
performed with Cdk5, p35, or pan-Trk antibody. Interest-
ingly, all three Trk receptors were observed to associate with
Cdk5 (Figure 1B) and p35 (Figure 1C), while no association
was observed when immunoprecipitation was performed with
IgG control. Since both TrkB and its ligand BDNF are
abundantly expressed in the brain throughout development,
we next proceeded to verify the interaction between TrkB
and Cdk5/p35 in postnatal brains. We found that TrkB
associated with both p35 and Cdk5 in postnatal day 7 (P7) rat
brain lysates (Figure 1D). Furthermore, Flag-tagged Cdk5
pulled down TrkB from the membrane fraction of adult brain
lysates (Figure 1E). These observations collectively suggest
that TrkB interacted with Cdk5/p35 in both postnatal and
adult brains. Since both p35 and Cdk5 are present in brain
lysates and likely exist as a complex, the observed interaction
between TrkB and Cdk5/p35 did not provide specific
information on whether TrkB associated specifically with
Cdk5 or p35. To delineate between these two possibilities, the
interaction between TrkB, p35, and Cdk5 was examined in
p35þ/þ and p35/ brain lysates (Figure 1F). Interestingly, we
found that in the absence of p35, the association between
Cdk5 and TrkB was essentially abolished, indicating that p35
was required for the association between Cdk5 and TrkB in
vivo.
Cdk5 Phosphorylated TrkB at Ser478
We next proceeded to examine if Trk receptors, TrkB in
particular, served as Cdk5 substrates using in vitro kinase
assay. TrkA, TrkB, and TrkC were overexpressed in COS7
cells and immunoprecipitated by pan-Trk antibody. Incuba-
tion with Cdk5/p25 revealed that TrkB and TrkC, but not
TrkA, were phosphorylated by Cdk5/p25 in vitro (Figure 2A).
This is in agreement with the lack of Cdk5 consensus sites in
TrkA, and points to the possibility that Cdk5 may phosphor-
ylate TrkB and TrkC at the Cdk5 consensus sites at the
juxtamembrane region (Figure 1A). To examine this possi-
bility, a GST fusion protein containing only the juxtamem-
brane region of TrkB was prepared. In vitro kinase assay
verified that Cdk5/p35 phosphorylated TrkB at the juxta-
membrane region (Figure 2B). It has previously been
proposed that p25 and p35 may confer different substrate
specificities. Results from our in vitro kinase assay suggested
that Cdk5 phosphorylated TrkB regardless of whether it was
activated by p25 or p35, although further studies will be
required to delineate the relative contributions of p25 and
p35 to endogenous phosphorylation of TrkB by Cdk5.
We were next interested in identifying the Cdk5 phos-
phorylation site(s) on TrkB. Three TrkB-juxtamembrane
region mutants were generated: TrkB M1, where Ser478
was mutated to alanine; TrkB M2, where Thr489 was mutated
to alanine; and TrkB DM, where both Ser478 and Thr489
were mutated to alanine. Interestingly, phosphorylation of
the TrkB-juxtamembrane region was almost completely
abolished when Cdk5/p25 was incubated with TrkB M1 or
TrkB DM (Figure 2C), thus revealing that Ser478 was
required for Cdk5-mediated phosphorylation of the TrkB-
juxtamembrane region. We further verified the importance
of this site for Cdk5-mediated phosphorylation of TrkB by
generating a phospho-specific TrkB antibody against Ser478.
Preincubation of the antibody with blocking peptide
prevented detection of Ser478-phosphorylated TrkB, indi-
cating that the antibody was sufficiently specific (Figure 2D).
Full-length TrkB mutants lacking the potential Cdk5
phosphorylation sites were overexpressed with or without
Cdk5/p35 in HEK293T cells. Interestingly, Ser478-phos-
phorylated TrkB was not observed in the absence of Cdk5/
p35, indicating that Cdk5 was essential for the phosphor-
ylation of TrkB at Ser478 in HEK293T cells. More
importantly, when TrkB mutants lacking Ser478 were
expressed (TrkB M1 and TrkB DM), phosphorylation of
TrkB at Ser478 was essentially abolished (Figure 2E). Taken
together, our observations indicate that Cdk5 phosphory-
lated TrkB at Ser478 at the juxtamembrane region of TrkB.
Author Summary
Accurate transmission of information in the nervous system requires
the precise formation of contact points between neurons. Regu-
lation of these contact sites involves fine tuning the number and
branching of dendritic processes on neurons. Throughout develop-
ment, several secreted factors act to regulate dendrite number and
branching. One important family of these factors is neurotrophins,
which are indispensable for the survival and development of
neurons. For example, stimulation of hippocampal neurons with one
neurotrophin, brain-derived neurotrophic factor (BDNF), increases
the number of dendrites directly extending from the cell body. Here,
we report that BDNF-stimulated dendritic growth requires phos-
phorylation of the BDNF receptor, TrkB, by a kinase known as cyclin-
dependent kinase 5 (Cdk5). Inhibiting phosphorylation of TrkB by
Cdk5 essentially abolishes the induction of dendrites by BDNF. Our
observations reveal that Cdk5 serves as a regulator of neurotrophin
function. Since Cdk5 and neurotrophins both play essential roles in
neuronal development, our findings suggest that the interplay
between Cdk5 and TrkB may also be implicated in the regulation of
other biological processes during development.
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Figure 1. TrkB Interacted with Cdk5 and p35
(A) TrkA, TrkB, and TrkC all contain proline-directed serine/threonine residues in the juxtamembrane region of the receptors (indicated by arrows).
Nonetheless, only TrkB and TrkC contain Cdk5 consensus sites S/TPXK/H/R.
(B) Cell lysates from HEK293T cells overexpressing Cdk5 and TrkA, TrkB, or TrkC were immunoprecipitated (IP) with Cdk5 antibody and immunoblotted
with pan-Trk antibody. TrkA, TrkB, and TrkC were all observed to associate with Cdk5.
(C) Cell lysates from HEK293T cells overexpressing p35 and TrkA, TrkB, or TrkC were immunoprecipitated with p35 antibody and immunoblotted with
pan-Trk antibody. TrkA, TrkB, and TrkC were all observed to associate with p35.
(D) Brain lysate from P7 rat brain was immunoprecipitated with pan-Trk, p35, or Cdk5 antibody and immunoblotted with p35, Cdk5, and TrkB
antibodies. Rabbit normal IgG was used as a control. TrkB was observed to associate with both p35 and Cdk5 in P7 rat brain.
(E) The membrane fraction of adult brain lysates was incubated with or without Flag-tagged Cdk5. Flag-tagged Cdk5 pulled down TrkB from the
membrane fraction of adult brain lysates.
(F) Brain lysates from P7 p35þ/þ or p35/mouse brains were immunoprecipitated with p35 and Cdk5 antibodies and immunoblotted with p35, Cdk5,
and TrkB antibodies. Rabbit normal IgG served as a control. Association between Cdk5 and TrkB was abolished in p35/ brain, indicating that p35 was
required for the association between Cdk5 and TrkB.
doi:10.1371/journal.pbio.0050063.g001
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Ser478 Phosphorylation of TrkB Required Cdk5 Activity In
Vivo
To further examine if Cdk5 is essential for phosphorylation
of TrkB at Ser478 in vivo, we examined the effect of
inhibiting Cdk5 activity on phospho-Ser478 (p-Ser478) TrkB
levels in cortical neurons. We found that at basal level, TrkB
was weakly phosphorylated at Ser478. Interestingly, stimula-
tion with BDNF led to a marked increase in p-Ser478 TrkB
levels, indicating that phosphorylation of TrkB at Ser478 was
at least in part ligand dependent. Remarkably, treatment with
Cdk5 selective inhibitor roscovitine (Ros) almost abrogated
the BDNF-triggered increase in p-Ser478 TrkB levels (Figure
3A), suggesting that Cdk5 was involved in the BDNF-
stimulated component of TrkB Ser478 phosphorylation. To
further establish the involvement of Cdk5 in Ser478
phosphorylation of TrkB in vivo, the levels of p-Ser478 TrkB
in cdk5þ/þ and cdk5/ brain lysates were examined. Impor-
tantly, we found that Ser478-phosphorylated TrkB was
basically undetectable in Cdk5/ brain lysates (Figure 3B).
Similarly, cortical neurons prepared from Cdk5/ brains
exhibited undetectable levels of p-Ser478 TrkB. In addition,
BDNF stimulation failed to trigger an increase in p-Ser478
TrkB levels (Figure 3C). These observations strongly suggest
Figure 2. Cdk5 Phosphorylated TrkB at Ser478
(A) Lysates from COS7 cells overexpressing TrkA, TrkB, and TrkC were immunoprecipitated with pan-Trk antibody and incubated with Cdk5/p25 in an in
vitro kinase assay. TrkB and TrkC, but not TrkA, were phosphorylated by Cdk5/p25.
(B) GST-TrkB-juxtamembrane fusion protein was incubated with increasing amount of Cdk5/p35 and subjected to an in vitro kinase assay. Histone H1
served as control to verify the activity of the Cdk5 kinase. The TrkB-juxtamembrane regionwas phosphorylated by Cdk5/p35 in a dose-dependentmanner.
(C) Purified WT GST-TrkB-juxtamembrane fusion protein and mutants (M1, M2, and DM) were incubated with Cdk5/p25 in an in vitro kinase assay. While
WT and M2 were strongly phosphorylated by Cdk5/p25, phosphorylation of M1 and DM were markedly attenuated. Quality of the purified GST and GST-
fusion proteins used in the GST pull-down assay was verified by Coomassie blue staining.
(D) Characterization of p-Ser TrkB antibody raised against phosphorylated Ser478 of TrkB. TrkB was overexpressed with or without p35/Cdk5 in HEK293T
cells. Preincubation of purified p-Ser478 TrkB antibody with blocking peptide completely abolished detection of Ser478 phosphorylation of TrkB.
(E) Full-length TrkB WT, M1, M2, and DM were overexpressed with or without Cdk5/p35 in HEK293T cells. In the absence of Cdk5/p35, Ser478-
phosphorylated TrkB (p-Ser TrkB) was not detected. Overexpression of Cdk5/p35 resulted in phosphorylation of TrkB WT at Ser478, but phosphorylation
at Ser478 was essentially abolished when TrkB M1 and DM were overexpressed. IP, immunoprecipitation.
doi:10.1371/journal.pbio.0050063.g002
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that Cdk5 is essential for phosphorylation of TrkB at Ser478
in vivo, and that BDNF-stimulated increase in Ser478
phosphorylation of TrkB requires Cdk5 activity.
BDNF Treatment Enhanced Cdk5 Activity
Since BDNF stimulation was observed to increase Ser478
phosphorylation of TrkB, and Cdk5 was required for
phosphorylating TrkB at Ser478, we were interested to
examine if BDNF stimulation affects Cdk5 activity. BDNF
has previously been observed to increase Cdk5 activity after 3
d of BDNF stimulation in cortical neurons [11]. In agreement
with this observation, we found that BDNF treatment led to
an increase in Cdk5 activity within 15 min of BDNF
stimulation (Figure 4A). More importantly, addition of Trk
inhibitor K252a essentially abolished BDNF-triggered in-
crease in Cdk5 activity, indicating that the increase in Cdk5
activity was dependent on TrkB activation (Figure 4B). It has
previously been demonstrated that Cdk5 activity is enhanced
by phosphorylation at Tyr15 [12]. Given the activation of
tyrosine kinase activity of TrkB upon ligand stimulation, we
were interested to investigate if BDNF treatment leads to
phosphorylation of Cdk5 at Tyr15, thereby enhancing its
activity. We found that BDNF stimulation enhanced associ-
ation between Cdk5 and TrkB in cortical neurons (Figure 4C).
More importantly, in vitro kinase assay using purified TrkB
and Cdk5 revealed that TrkB phosphorylated Cdk5 at Tyr15
(Figure 4D and 4E). TrkB-mediated phosphorylation of Cdk5
was abolished with the addition of Trk inhibitor K252a,
further verifying that Tyr15 phosphorylation of Cdk5 was
TrkB dependent (Figure 4E). These observations collectively
indicate that upon BDNF stimulation, Cdk5 was recruited to
TrkB and phosphorylated by TrkB at Tyr15, thus leading to
enhanced Cdk5 activity to promote phosphorylation of TrkB
at Ser478.
Ser478 Phosphorylation of TrkB Was Required for BDNF-
Stimulated Dendritic Growth
Given the neural-specific nature of Cdk5, its abundant
expression throughout development, and its essential role in
the phosphorylation of TrkB at Ser478, we were interested in
examining the biological significance of this phosphorylation
on the downstream functions of BDNF/TrkB signaling. As a
first step, we examined if Cdk5-mediated phosphorylation of
TrkB affects TrkB activation and downstream signaling
cascades. Interestingly, we found that inhibition of Cdk5
activity by Cdk5 selective inhibitor Ros only marginally
affected tyrosine phosphorylation of TrkB and initiation of
downstream signaling pathways including phosphorylation of
Figure 3. Ser478 Phosphorylation of TrkB Required Cdk5 Activity In Vivo
(A) BDNF stimulation resulted in an increase in p-Ser478 TrkB (p-Ser TrkB) levels in cortical neurons. Treatment with Cdk5 selective inhibitor Ros (25 lM)
inhibited the BDNF-induced increase in p-Ser478 TrkB, although Ros treatment also resulted in a slight increase in basal p-Ser478 TrkB.
(B) cdk5þ/þ and cdk5/ brain lysates were immunoblotted against TrkB, phospho-TrkB at Ser478, and b-actin as loading control. p-Ser478 TrkB was
almost completely absent in cdk5/ brain, indicating the importance of Cdk5 in the phosphorylation of TrkB at Ser478 in vivo.
(C) Cortical neurons isolated from cdk5þ/þ and cdk5/ brain were treated with BDNF for different periods. Interestingly, while BDNF enhanced TrkB
Ser478 phosphorylation in cdk5þ/þ cortical neurons, TrkB Ser478 phosphorylation was not detected in cdk5/ neurons, nor did BDNF stimulation
enhance Ser478 phosphorylation, indicating that BDNF-stimulated increase in TrkB Ser478 phosphorylation requires Cdk5 activity.
doi:10.1371/journal.pbio.0050063.g003
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Figure 4. BDNF Enhanced Cdk5 Activity
(A) Cortical neurons were stimulated with BDNF for different time intervals. Lysates were immunoprecipitated (IP) with p35 antibody and subjected to
in vitro kinase assay using histone H1 as substrate. BDNF stimulation for 15 min resulted in a marked increase in Cdk5 activity in cortical neurons.
Quantification of the changes in phospho-Histone H1 level following BDNF stimulation was normalized to the value obtained from untreated cultures
(time 0) and is shown in the histogram. *, p , 0.05.
(B) Addition of Trk inhibitor K252a abolished BDNF-induced increase in Cdk5 activity. Cortical neurons were pretreated with vehicle control (DMSO) or
K252a for 30 min before stimulation with BDNF for 15 min. Lysates were immunoprecipitated with p35 antibody and subjected to in vitro kinase assay
using histone H1 as substrate. We found that K252a pretreatment markedly reduced the increase in Cdk5 activity triggered by BDNF stimulation,
indicating that the induction of Cdk5 activity was dependent on TrkB activation. Quantification of the changes in phospho-Histone H1 level following
BDNF stimulation in the presence or absence of K252a treatment was normalized to the value obtained from untreated cultures (time 0) and is shown in
the histogram. *, p , 0.05.
(C) Cortical neurons were treated with BDNF for 20 min. Lysates were immunoprecipitated with p35 antibody and immunoblotted with TrkB, p35, or
Cdk5 antibody. While association between Cdk5 and p35 was not affected by BDNF stimulation, association between p35 and TrkB increased following
20 min of BDNF stimulation.
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Erk1/2, Akt, and CREB (data not shown). Indeed, BDNF-
stimulated increase in TrkB tyrosine phosphorylation was
weakly affected in cdk5/ cortical neurons (Figure 3C).
Furthermore, activation of Akt and Erk1/2 following BDNF
stimulation was also comparable in cdk5þ/þ and cdk5/ cortical
neurons (data not shown). Our observations thus revealed
that Cdk5-mediated phosphorylation of TrkB did not
significantly affect activation of the receptor, nor its
initiation and recruitment of downstream signaling pathways.
Although Cdk5-mediated phosphorylation of TrkB had
negligible effect on the downstream signaling of TrkB, it
cannot be ruled out that Ser478 phosphorylation of TrkB is
essential for the downstream functions of BDNF/TrkB
signaling. We thus sought to examine if Cdk5-mediated
phosphorylation of TrkB affects its downstream functions.
BDNF has been observed to stimulate dendrite growth and
development in hippocampal neurons [13,14]. In accordance
with earlier observations, BDNF treatment led to a marked
increase in the number of primary dendrites in hippocampal
neurons (Figure 5A), although the length and branching of
dendrites were not affected (data not shown). Interestingly,
treatment with Cdk5 selective inhibitor Ros almost com-
pletely abolished the BDNF-stimulated dendritic growth,
without affecting the basal number of dendrites (Figure 5A).
Furthermore, overexpression of dominant negative (DN)
Cdk5 (Figure 5B) and transfection with Cdk5 short interfer-
ing RNA (siRNA) (Figure 5C) both abrogated BDNF-induced
increase in primary dendrites. More importantly, BDNF
similarly failed to induce an increase in primary dendrites
in cdk5/ hippocampal neurons (Figure 5D). These observa-
tions collectively reveal that Cdk5 activity was required for
BDNF-induced increase in primary dendrites in hippocampal
neurons. To verify the importance of Ser478 phosphorylation
of TrkB in BDNF-triggered dendritic growth, TrkB wild-type
(WT) or TrkB M1 was overexpressed in hippocampal neurons.
Remarkably, overexpression of TrkB M1 similarly abolished
the BDNF-induced increase in primary dendrites (Figure 5E).
Taken together, our data indicate that Cdk5-mediated
phosphorylation of TrkB at Ser478 was required for BDNF-
triggered dendritic growth in hippocampal neurons.
Cdk5-Mediated Phosphorylation of TrkB Affected BDNF-
Induced Dendritic Growth through Attenuation of Cdc42
Activity
Rho GTPases, including RhoA, Rac1, and Cdc42, are key
regulators of actin cytoskeleton dynamics. Since BDNF
stimulation has been observed to activate Rac1 and Cdc42
in neurons [15], we were interested to delineate if Rho
GTPases contribute to BDNF-stimulated dendritic growth. To
investigate if Rho GTPases are involved, and to identify the
Rho GTPase(s) implicated, hippocampal neurons were trans-
fected with WT or DN Rac1, Cdc42, or RhoA. We found that
while overexpression of WT and DN Rac1 increased the basal
number of dendrites in the absence of BDNF treatment,
overexpression of both forms of Rac1 abolished BDNF-
stimulated dendritic growth. On the other hand, while
overexpression of DN RhoA slightly enhanced primary
dendrites irrespective of BDNF stimulation, overexpression
of both WT and DN forms of RhoA inhibited BDNF-
stimulated dendritic growth. Remarkably, in contrast to the
inhibition of BDNF-stimulated dendritic growth in cells
overexpressing WT Rac1 and RhoA, BDNF stimulation of
hippocampal neurons overexpressing WT Cdc42 resulted in
an increase in primary dendrites, which was nearly abolished
by overexpression of DN Cdc42 (Figure 6A). Our observations
therefore suggest that while Rac1 and RhoA may also
modulate BDNF-stimulated dendritic growth, it is the
activation of Cdc42 following BDNF stimulation that most
likely mediates the increase in primary dendrites by BDNF.
To examine if phosphorylation of TrkB by Cdk5 affects
dendritic growth through modulating BDNF-triggered acti-
vation of Cdc42, we first examined if the BDNF-induced
increase in Cdc42 activity was affected by treatment with
Cdk5 selective inhibitor Ros. In agreement with earlier
findings, BDNF treatment resulted in an increase in Cdc42
activity. Interestingly, treatment with Ros significantly re-
duced BDNF-induced Cdc42 activity in cortical neurons
(Figure 6B), suggesting that Cdk5 activity was involved in
BDNF-triggered activation of Cdc42. To investigate if the
reduction in Cdc42 activity contributes to the abrogation of
BDNF-induced dendritic growth following attenuation of
Cdk5 activity, the effect of overexpressing constitutively
active (CA) Cdc42 with TrkB M1 on BDNF-induced dendritic
growth was examined. Remarkably, overexpression of CA
Cdc42 reversed the abrogation of BDNF-induced dendritic
growth by TrkB M1 (Figure 6C). More importantly, while
overexpression of CA Cdc42 had negligible effect on BDNF-
stimulated increase in primary dendrites in Cdk5þ/þ neurons,
overexpression of CA Cdc42 similarly rescued the lack of
dendritic growth in cdk5/ neurons following BDNF stim-
ulation (Figure 6D). These observations strongly suggest that
Cdk5-mediated phosphorylation of TrkB at Ser478 was
essential for the BDNF-triggered increase in primary den-
drites through modulating BDNF-induced Cdc42 activity.
Discussion
In the current study, we report the identification of TrkB as
a novel Cdk5 substrate by providing evidence that Cdk5
phosphorylates TrkB at Ser478, located at the intracellular
juxtamembrane region of the receptor. The near absence of
Ser478-phosphorylated TrkB in cdk5/ brain underscores the
importance of Cdk5 in this phosphorylation in vivo. More
importantly, we found that Cdk5-mediated phosphorylation
of TrkB is required for BDNF-stimulated increase in primary
dendrites. Furthermore, we demonstrated that Cdk5 activity
is involved in BDNF-induced increase in Cdc42 activity,
which underlies BDNF-induced dendritic growth in hippo-
campal neurons. Overexpression of CA Cdc42 restored
BDNF-stimulated increase in primary dendrites in cdk5/
neurons, lending further support that Cdk5-mediated phos-
phorylation of TrkB at Ser478 is essential for BDNF-induced
(D) Recombinant TrkB was incubated with GST-Cdk5 in an in vitro kinase assay. TrkB was found to phosphorylate GST-Cdk5 (middle lane).
(E) GST-Cdk5 and recombinant TrkB were pretreated with vehicle (DMSO) or K252a for 10 min, subjected to in vitro kinase assay, and immunoblotted
with antibodies against phospho-tyrosine (p-Tyr) and the Tyr15 phosphorylated form of Cdk5 (pTyr15 Cdk5). Cdk5 was phosphorylated by TrkB at Tyr15.
Addition of K252a abolished phosphorylation of Cdk5 by TrkB, further verifying that Cdk5 was phosphorylated by TrkB.
doi:10.1371/journal.pbio.0050063.g004
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Cdc42 activation and increase in primary dendrites. Our
findings therefore reveal an unanticipated role of Cdk5 in
mediating downstream functions of Trk signaling.
Activation of Rho GTPases has been implicated in a
number of functions downstream of neurotrophin stimula-
tion. For example, a recent study reported that synaptic
maturation involves BDNF-stimulated increase in Cdc42
activity [16]. In addition, activation of Cdc42 is involved in
the regulation of retinal growth cone filopodia by BDNF [17].
Activation of Rac1 following neurotrophin stimulation has
also been observed to mediate neuronal migration triggered
by neurotrophin treatment [18]. Our observation that BDNF-
Figure 5. Attenuation of Cdk5 Activity Abolished BDNF-Induced Increase in Primary Dendrites in Hippocampal Neurons
(A) Hippocampal neurons were stimulated with BDNF for 3 d in the presence or absence of Ros (10 lM). Interestingly, while BDNF treatment markedly
enhanced the number of primary dendrites, treatment with Ros abrogated the increase.
(B) Hippocampal neurons were transfected with Cdk5 or DN Cdk5. Twenty-four hours after transfection, cells were exposed to BDNF for 3 d.
Overexpression of DN Cdk5 abolished the BDNF-induced increase in primary dendrites.
(C) Hippocampal neurons were transfected with Cdk5 siRNA or control siRNA. Twenty-four hours after transfection, cells were exposed to BDNF for 3 d.
Transfection with Cdk5 siRNA attenuated Cdk5 expression in hippocampal neurons. More importantly, BDNF-induced increase in primary dendrites was
abrogated in Cdk5 siRNA–transfected cells.
(D) Hippocampal neurons isolated from cdk5þ/þ and cdk5/ brains were treated with BDNF for 3 d. BDNF treatment failed to enhance primary dendrites
in Cdk5/ neurons.
(E) Hippocampal neurons were transfected with TrkB WT or TrkB M1. Twenty-four hours after transfection, cells were exposed to BDNF for 3 d.
Overexpression of TrkB M1 markedly reduced the BDNF-induced increase in primary dendrites.
Scale bar ¼ 10 lm. *, p , 0.05.
doi:10.1371/journal.pbio.0050063.g005
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stimulated increase in Cdc42 activity contributes to the
increase in primary dendrites corroborates these studies. It is
interesting to note that overexpression of WT and DN Rac1
and RhoA also inhibited BDNF-induced increase in primary
dendrites. While it is rather intriguing to observe similar
actions by the WT and DN forms of these two Rho GTPases,
our observation nonetheless suggests that Rac1 and RhoA
may also play a role in BDNF-stimulated dendritic growth.
Further studies will be required to delineate their involve-
ments in BDNF-dependent regulation of dendritic develop-
ment.
Although different Rho GTPases have been identified as
essential downstream mediators of neurotrophin functions,
much less is known about the mechanisms by which neuro-
trophin treatment results in Rho GTPase activation, and how
this process is regulated. The activity of Rho GTPases is
controlled by a number of factors. Conversion from the GDP-
bound, inactive state to the GTP-bound, active state is
facilitated by guanine nucleotide exchange factors (GEFs).
The activated Rho GTPases then translocate to the plasma
membrane, where they activate other downstream effectors
such as PAK1 to modulate actin dynamics [19]. Indeed,
neurotrophins have recently been observed to induce Rho
GTPase activity through recruitment of a number of GEFs.
TrkA was demonstrated to bind to Kalirin, an association that
is essential for NGF-induced Rac1 activation and neurite
outgrowth [20]. Furthermore, NGF treatment induces plasma
membrane translocation of the GEFs Vav2 and Vav3, an event
that is required for activation of Rac1 and Cdc42 and the
induction of neurite outgrowth following NGF treatment in
PC12 cells [21]. NGF also stimulates activation of the Rac-
specific GEF p-Rex1 in PC12 cells [18]. Two recent studies
Figure 6. Cdk5-Mediated Phosphorylation of TrkB Affected BDNF-Induced Dendritic Growth through Attenuation of Cdc42 Activity
(A) Hippocampal neurons were transfected with the WT or DN form of Rac1, RhoA, or Cdc42. Twenty-four hours after transfection, cells were exposed to
BDNF for 3 d. Overexpression of DN Cdc42 markedly reduced BDNF-induced increase in primary dendrites compared to overexpression of WT Cdc42,
indicating that Cdc42 may contribute to the BDNF-dependent induction of dendritic growth in hippocampal neurons.
(B) Cortical neurons were pretreated with Cdk5 selective inhibitor Ros or vehicle (DMSO) for 30 min prior to treatment with BDNF for different time
intervals. Ros pretreatment markedly reduced BDNF-induced increase in Cdc42 activity following 15 and 30 min of BDNF treatment, indicating that
Cdk5 activity was involved in BDNF-triggered Cdc42 activation. Quantification of the changes in Cdc42 activity following BDNF stimulation with or
without Ros pretreatment was normalized to the value obtained for the DMSO-treated group at time 0 and is shown in the histogram. *, p , 0.05.
(C) TrkB WT or TrkB M1 mutant were co-transfected with WT or CA Cdc42 in hippocampal neurons. Twenty-four hours after transfection, cells were
exposed to BDNF for 3 d. Overexpression of CA Cdc42 reversed the abrogation of BDNF-induced increase in primary dendrites following overexpression
of TrkB M1. *, p , 0.05.
(D) Hippocampal neurons isolated from cdk5þ/þ and cdk5/ brains were transfected with WT or CA Cdc42. Twenty-four hours after transfection, cells
were exposed to BDNF for 3 d. Overexpression of CA Cdc42 rescued the lack of dendritic growth following BDNF treatment in Cdk5/ hippocampal
neurons. *, p , 0.05.
doi:10.1371/journal.pbio.0050063.g006
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reveal that neurotrophin stimulation in Schwann cells also
leads to Rho GTPase activation through activation of GEFs.
TrkC activation results in activation of the Cdc42-specific
GEF Dbs [22] and Rac-specific GEF Tiam1 [23], both of which
are required for NT-3-stimulated Schwann cell migration.
Finally, TrkB was also recently demonstrated to bind and
phosphorylate Tiam1 to mediate a BDNF-triggered change in
cell shape [24].
On the other hand, recent studies accentuate the impor-
tance of membrane recruitment of Rho GTPase to lipid rafts
for the function of these Rho GTPases. Lipid rafts are
microdomains in plasma membrane rich in cholesterol and
sphingolipids. Targeting of activated Rac1 to lipid rafts is
required for activation of downstream effector Pak1 [25].
More importantly, neurotrophin-triggered Rac1 activation
and morphological changes in hippocampal neurons have
also been observed to require localization of Rac1 to lipid
rafts [26]. Finally, BDNF has also been observed to increase
Cdc42 activity in cerebellar granule neurons through
enhancing calcium influx following the activation of PLCc
and PI3K pathways, a series of events that are essential for
BDNF-mediated growth cone turning [27]. While a number of
mechanisms have been postulated to underlie neurotrophin-
mediated activation of Rho GTPases, it appears that the
mechanisms implicated may vary with different downstream
functions of Trk activation and the GEF involved.
In the current study, we demonstrated that Ser478
phosphorylation of TrkB by Cdk5 is essential for the Cdc42-
dependent increase in primary dendrites triggered by BDNF,
thus adding a new regulatory component to the mechanisms
involved in Rho GTPase activation by neurotrophin.
Although the precise downstream pathways by which this
phosphorylation affects Cdc42 activation remains to be
determined, our observations provide some interesting
insights. First of all, while inhibition of Cdk5-mediated TrkB
phosphorylation at Ser478 essentially abolished BDNF-in-
duced increase in primary dendrites, it was surprising to
observe that Cdk5 activity had a negligible effect on TrkB
activation and initiation of downstream signaling pathways.
This suggests that Cdk5 activity probably did not affect
BDNF-dependent activation of Cdc42 and the induction of
primary dendrites through modulating activation of down-
stream signaling. This is unexpected because BDNF-stimu-
lated increase in primary dendrites was previously observed
to depend on PI3K/Akt pathways in cortical neurons [28].
Nonetheless, accumulating evidence reveals that the location
at which Trk receptors are activated may play a pivotal role in
determining the precise downstream significance of Trk
activation. For example, BDNF-induced increase in primary
dendrites was recently demonstrated to involve TrkB
activation in the lipid rafts [13]. In addition, retrograde
transport of activated Trk receptors as signaling endosomes is
emerging as a key regulator of neuronal survival [29]. Since
we examined changes in TrkB downstream signaling cascades
only in total lysates, it remains possible that Cdk5 activity may
specifically affect TrkB signaling only at certain subcellular/
plasma membrane compartments.
Secondly, overexpression of CA Cdc42 restored BDNF-
induced dendritic growth in cdk5/ neurons and in neurons
overexpressing TrkB M1 (Figure 6), suggesting that main-
tenance of Cdc42 activation was sufficient to overcome the
lack of BDNF-stimulated dendritic growth when Cdk5-
mediated TrkB phosphorylation was absent. It thus appears
that Cdk5 may impair BDNF-induced Cdc42 activation by
affecting activation of the Rho GTPase. On the other hand, it
should also be noted that overexpression of both the DN and
CA forms of Cdc42 had a negligible effect on the basal
number of primary dendrites in both cdk5þ/þ and cdk5/
neurons (Figure 6). Our observation is in agreement with an
earlier study demonstrating that overexpression of DN or CA
Cdc42 had no effect on the number of primary dendrites in
chick spinal neurons [30]. In addition, it is consistent with the
observation that modulation of Cdk5 activity or overexpres-
sion of TrkB M1 affected only BDNF-induced dendritic
growth, without affecting the basal number of dendrites.
Nonetheless, the inability of CA Cdc42 to mimic BDNF in the
induction of primary dendrites suggests that activation of
Cdc42 per se was insufficient to trigger dendritic growth in
the absence of BDNF, and that additional, BDNF-dependent
event(s) are required for the induction of dendritic growth by
BDNF. Although the precise pathways implicated remain to
be identified, it is tempting, in light of the emerging
importance of lipid rafts in the activation of Rho GTPase,
to speculate that BDNF may be required to stimulate
translocation of activated Cdc42 to lipid rafts. In support of
this hypothesis, it was observed that activation of Rac1
depends on the translocation of the activated Rho GTPase to
lipid rafts [25,26]. In addition, in the absence of cholesterol,
CA Rac1 failed to translocate to plasma membrane in
fibroblasts [25]. More importantly, depletion of cholesterol
similarly abolished BDNF-induced increase in primary
dendrites in hippocampal neurons [13]. These observations
collectively suggest that the inability of CA Cdc42 to increase
dendritic growth in the absence of BDNF treatment may be
related to the lack of CA Cdc42 translocation to lipid rafts,
which may potentially be induced by BDNF treatment. A
thorough investigation of the importance of lipid rafts in
Cdc42 activation and primary dendrite induction by BDNF
will shed light on the mechanisms by which BDNF-triggered
dendritic growth is regulated.
Given the near absence of Ser478-phosphorylated TrkB in
cdk5/ brain, we believe that Cdk5 functions as the predom-
inant kinase for this phosphorylation in vivo. Nonetheless, it
was interesting to note that prior to BDNF stimulation, a
basal level of Ser478-phosphorylated TrkB was detected in
cortical neurons that was not inhibited by pretreatment with
the Cdk5 inhibitor Ros. This may suggest that other serine
kinases are present to phosphorylate TrkB at Ser478 in the
absence of BDNF stimulation. Nonetheless, given the marked
inhibition of BDNF-stimulated increase in TrkB phosphor-
ylation by Ros, we believe that Cdk5 is essential for the BDNF-
dependent component of TrkB phosphorylation at Ser478.
Given the abundant expression of Cdk5 and TrkB in
neurons throughout development, and their respective
concentration at the synapse, it would be interesting to
examine if Cdk5 activity is also involved in other downstream
functions of TrkB signaling, such as the regulation of
neuronal survival and synaptic plasticity. Preliminary findings
from our laboratory reveal that Cdk5 activity is also required
for BDNF-stimulated neuronal survival in cortical neurons
(unpublished data). In addition, the juxtamembrane region of
Trk receptors has been associated with the regulation of Trk
receptor internalization [31] and degradation [32]. Further
investigation of whether this phosphorylation also affects the
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internalization and degradation of the receptor would
provide further insights into the biological significance of
this phosphorylation. In addition, since Cdk5 was observed to
associate with TrkA without phosphorylating the receptor,
further delineation of the consequences of this interaction
would be essential for thoroughly understanding the crosstalk
between Trk receptors and Cdk5. A preliminary study
revealed that, similar to TrkB, TrkA phosphorylates Cdk5 at
Tyr15 (unpublished data). The differential interaction of
TrkA and TrkB with Cdk5, together with the differential
localization of TrkA and TrkB in different neuronal
populations, may provide a novel mechanism by which
Cdk5 can regulate the signaling of different neuronal
populations. In conclusion, our findings have provided
evidence for a regulatory role of Cdk5 in Trk-induced
dendritic growth, and lend support for an emerging role of
Cdk5 as a regulator of RTK signaling. Given the importance
of neurotrophin/Trk signaling in almost all aspects of
neuronal development and function, our findings will likely
have far-reaching implications for further elucidating the
signaling mechanisms involved in the regulation of neuronal
survival, synapse formation, and synaptic plasticity.
Materials and Methods
Antibodies, DNA constructs, and siRNAs. The antibodies against
Trk (C-14), Cdk5 (DC-17), p35, and Shc were purchased from Santa
Cruz Biotechnology (http://www.scbt.com). The antibodies against
TrkB and SH2B were from BD Biosciences (http://www.bdbiosciences.
com). The polyclonal antibodies recognizing phospho-TrkA (Tyr490),
p44/42 mitogen-activated protein kinase (Erk1/2), phospho-p44/42
mitogen-activated protein kinase, AKT, phospho-AKT (Ser473),
CREB, and phospho-Ser133 CREB were obtained from Cell Signaling
Technology (http://www.cellsignal.com). Antibodies specific for actin
and b-tubulin type III were from Sigma-Aldrich (http://www.
sigmaaldrich.com). Antibody against the p-Ser478 of TrkB was raised
by synthetic peptide (CISNDDDSApSPLHHIS; Bio-Synthesis, http://
www.biosyn.com) and purified using AminoLink Kit (Pierce, http://
www.piercenet.com).
Expression vectors of p35, Cdk5, and DN Cdk5 were prepared as
previously described [3]. Flag-tagged and GST-tagged Cdk5 were
generated by PCR, and subcloned into the mammalian expression
vectors pcDNA3 (Invitrogen, http://www.invitrogen.com) and pGEX-
6P-1 (Amersham Biosciences, http://www5.amershambiosciences.
com), respectively. HA-tagged and GST-tagged Rac1, Cdc42, and
RhoA constructs were gifts from Yung-Hou Wong (Hong Kong
University of Science and Technology, Hong Kong). The expression
vectors of TrkA, TrkB, and TrkC were constructed as described [33].
Three TrkB mutants lacking the potential Cdk5 phosphorylation sites
were constructed by mutating Ser478 (TrkB M1), Thr489 (TrkB M2),
or both Ser478 and Thr489 (TrkB DM) to alanine using the
overlapping PCR technique, followed by subcloning into pcDNA3.
GST-TrkB-Juxta construct was generated by PCR and subcloned into
pGEX-6P-1. Protein purification was performed according to the
manufacturer’s protocol.
Stealth RNAi molecules for Cdk5 were prepared as previously
described [34]. The sequences used were: Cdk5 siRNA, CCUCCGG-
GAGAUCUGUCUACUCAAA; and control siRNA (Cdk5),
CCUAGGGCUAGCUGUUCAUCCCAAA.
Animals, primary cultures, and transfection. Cdk5 and p35
knockout mice were kindly provided by A. B. Kulkarni (National
Institutes of Health, Bethesda, Maryland) and T. Curran (St. Jude
Children’s Research Hospital, Memphis, Tennessee), and L. H. Tsai
(Harvard Medical School, Boston, Massachusetts), respectively. Mice
from different stages were collected and genotyped as described
[7,35].
Rat cortical and hippocampal neuron cultures were prepared as
previously described [33,34]. Subsequent to digestion with 0.25%
trypsin in Hank’s Balanced Salt Solution without Ca2þ and Mg2þ at 37
8C for 5 min, the reaction was stopped by 2.5% heat-inactivated horse
serum. The dissociated neurons were seeded in culture dishes coated
with 10 lg/ml poly-D-lysine. Two hours later the medium was
replaced by neurobasal medium supplemented with 2 mM L-
glutamine and 2% B27 supplement.
Selective Cdk5 inhibitor Ros (Calbiochem, http://www.
merckbiosciences.com/html/CBC/home.html) was used to inhibit
Cdk5 activity in primary neuron cultures. Primary cultures at 3 d
in vitro (DIV3) were treated with or without BDNF (50 ng/ml) in the
presence of Ros (10 or 25 lM) or DMSO for 3 d before harvesting or
fixation.
For transfection of primary cultures, cortical and hippocampal
neurons were seeded on coverslips in 12-well dishes at a cell density
of 2 3 105 per coverslip. Neurons were transfected using calcium
phosphate precipitation at DIV3. Twenty-four hours after trans-
fection, the cultures were treated with BDNF for 3 d.
Primary hippocampal neuron cultures on coverslips in 12-well
dishes were seeded at a cell density of 53104 per coverslip for siRNA
transfection. Cultures were transfected at DIV3 with Lipofectamine
2000 transfection reagent following the manufacturer’s protocols
(Invitrogen). The transfected cells were incubated at 37 8Cwith 5%CO2
for 24 h before treatment, and were then treated with BDNF for 3 d.
Cell cultures and transfection. COS7 cells and HEK293T cells were
obtained from American Type Culture Collection (http://www.atcc.
org). Both cells were maintained in DMEM supplemented with 10%
heat-inactivated fetal bovine serum, penicillin (50 units/ml), and
streptomycin (100 lg/ml) at 37 8C with 5% CO2. COS7 cells and
HEK293T cells were transfected using Lipofectamine Plus trans-
fection reagents following the supplier’s instructions (Invitrogen).
The cells were treated and harvested 24 h after transfection.
Protein extraction, immunoprecipitation, in vitro pull-down assay,
and Western blot analysis. Cells were lysed at 4 8C for 30 min in lysis
buffer (RIPA: 13 PBS, 1% NP40, 0.1% SDS, and 0.5% sodium
deoxycholate) with various protease inhibitors (1 mM phenylmethyl-
sulfonyl fluoride [PMSF], 1 mM sodium orthovanadate [NaOV], 2 lg/
ml antipain, 10 lg/ml leupeptin, 30 nM okadaic acid, 5 mM
benzamidine, and 10 lg/ml aprotinin). Brain tissues were homogen-
ized in lysis buffer (0.5% NP-40, 20 mM Tris-HCl, 150 mM NaCl, 1
mM EDTA, 1 mM EGTA, and 1 mM NaF [pH 7.5]) supplemented with
various protease inhibitors (1 mM PMSF, 1 mM NaOV, 2 lg/ml
antipain, 10 lg/ml leupeptin, 30 nM okadaic acid, 5 mM benzamidine,
and 10 lg/ml aprotinin). Proteins were resolved by SDS-PAGE and
subsequently electro-transferred onto a nitrocellulose membrane.
Immmunoblots were probed with the desired primary antibodies at 4
8C overnight. After washing with TBS-T, the corresponding HRP-
conjugated secondary antibody was added and incubated for 2 h at
room temperature. Proteins were then visualized using enhanced
chemiluminescence Western blotting detection reagents with refer-
ence to the supplier’s instructions (Amersham Biosciences).
For immunoprecipitation, 1–2 mg of protein lysates was incubated
with 1 lg of the corresponding antibody at 4 8C overnight with
rotation. Forty microliters of protein G Sepharose (Amersham
Biosciences) pre-washed with 13 PBS was added and rotated at 4 8C
for 1 h. After intense washing with the lysis buffer, the immunopre-
cipitated protein and its associated proteins were analyzed by SDS-
PAGE and Western blotting.
Flag-tagged protein was overexpressed in COS7 cells and the cell
lysate was obtained as described above. The cell lysate obtained was
incubated with anti-Flag M2 affinity gel (Sigma-Aldrich) at 4 8C
overnight with rotation. The Flag-tagged protein was pulled down by
the affinity gel, and the affinity gel was washed twice with lysis buffer
(0.5% NP-40, 20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, and 1 mM NaF [pH 7.5]) with various protease inhibitors (1
mM PMSF, 1 mM NaOV, 2 lg/ml antipain, 10 lg/ml leupeptin, 30 nM
okadaic acid, 5 mM benzamidine, and 10 lg/ml aprotinin). One to two
milligrams of proteins prepared from brain tissues was incubated
with the affinity gel, and the Flag-tagged protein pulled down by the
affinity gel for 1 h. The affinity gel was washed twice with lysis buffer
supplemented with protease inhibitors. The proteins pulled down by
the Flag-tagged protein were subjected to Western blot analysis.
In vitro kinase assay. Recombinant Cdk5/p35 and Cdk5/p25 were
kindly provided by Shin-Ichi Hisanaga (Tokyo Metropolitan Univer-
sity, Tokyo). TrkA, TrkB, and TrkC were immunoprecipitated from
transfected HEK293T cells, and used as substrates for reconstituted
Cdk5/p35 or Cdk5/p25 in the in vitro kinase assay. The kinase assay
was performed at 30 8C for 30 min in kinase buffer containing 100 lM
[c-32P] ATP as described [36]. To examine if TrkB phosphorylated
Cdk5, recombinant TrkB kinase domain (Upstate Biotechnology,
http://www.upstate.com) was incubated with GST-Cdk5 for 30 min at
30 8C, with or without Trk inhibitor K252a pretreatment (100 nM) for
10 min, in the presence of 100 lM [c-32P] ATP or cold ATP. To
examine if BDNF stimulated Cdk5 activity, primary cortical neurons
were treated with BDNF with or without 30 min of K252a pretreat-
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ment (100 nM). The immunoprecipitated Cdk5/p35 complexes from
the lysates were washed three times with lysis buffer and twice with
kinase buffer. The in vitro kinase reaction was performed at 30 8C for
30 min with kinase buffer containing 100 lM histone H1 peptide and
100 lM [c-32P] ATP as described [37]. The phosphorylated proteins
were resolved by SDS-PAGE. After the gel was dried, the phosphory-
lated proteins were visualized by autoradiography. For TrkB-
mediated Cdk5 phosphorylation, the phosphorylated protein was
resolved by SDS-PAGE, and blotted with phospho-Cdk2 (Tyr15; Santa
Cruz Biotechnology) or phosphotyrosine antibody (4G10; Upstate
Biotechnology).
GTPase activity assay. GTPase activity was measured as described
[38]. Briefly, cultured cortical neurons at DIV7 were pretreated with
DMSO or Ros for 30 min, followed by treatment with BDNF for
another 5 min. Cells were lysed at 4 8C and incubated with Pak1-PBD
agarose with constant rocking at 4 8C for 1 h. The proteins bound to
the beads were washed three times with lysis buffer at 4 8C, eluted in
SDS sample buffer, and analyzed for bound Cdc42 byWestern blotting
using monoclonal antibody against Cdc42 (Upstate Biotechnology).
GTPase activity was quantified by densitometry analysis of the blots.
Immunohistochemical analysis. Following fixation in 4% parafor-
maldehyde and 5% sucrose in PBS with Ca2þ and Mg2þ for 30 min, the
cells were washed three times with PBS, and were blocked with 1%
bovine serum albumin and 10% goat serum for 20 min. The cells were
then incubated with the corresponding primary antibody (1:150–500)
at 4 8C overnight, and were subsequently washed with PBS three
times. Following incubation with FITC or rhodamine conjugated
secondary antibody (1:1,000) for 1 h at room temperature, the cells
were washed again, stained with DAPI, and mounted with coverslips
and MOWIOL (Calbiochem). Mounted cells were visualized under
fluorescent microscope (Leica, http://www.leica.com).
Statistical analysis. All data were expressed as mean 6 standard
deviation. Statistical significance was determined by one-way analysis
of variance followed by Bonferroni’s post hoc test with 95%
confidence. A p-value of smaller than 0.05 was considered as
statistically significant.
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